Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis

Vaccine

Volumn 26, Issue 15, 2008, Pages 1902-1911

  Carrillo, Eugenia ^a   Crusat, Martín ^a   Nieto, Javier ^a   Chicharro, Carmen ^a   Thomas, Maria del Carmen ^b   Martínez, Enrique ^c   Valladares, Basilio ^c   Cañavate, Carmen ^a   Requena, Jose María ^d   López, Manuel Carlos ^b   Alvar, Jorge ^a   Moreno, Javier ^e  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Canine; Cytokine; HSP 70; Immunogenicity; KMP 11; Leishmania; PFR 2

Indexed keywords

GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; INTERLEUKIN 10; KINETOPLASTIDA MEMBRANE PROTEIN 11; MESSENGER RNA; PARAFLAGELLAR ROD PROTEIN 2; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOG; GENE EXPRESSION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; UPREGULATION; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DOGS; GENE EXPRESSION; HSP70 HEAT-SHOCK PROTEINS; LEISHMANIA INFANTUM; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LEUKOCYTES, MONONUCLEAR; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; TH1 CELLS;

EID: 40849114492     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.042     Document Type: Article

References (54)

1. Gramiccia M., and Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 35 11-12 (2005) 1169-1180
2. Solano-Gallego L., Morell P., Arboix M., Alberola J., and Ferrer L. Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology. J Clin Microbiol 39 2 (2001) 560-563
3. Travi B.L., Tabares C.J., Cadena H., Ferro C., and Osorio Y. Canine visceral leishmaniasis in Colombia: relationship between clinical and parasitologic status and infectivity for sand flies. Am J Trop Med Hyg 64 3-4 (2001) 119-124
4. Courtenay O., Quinnell R.J., Garcez L.M., Shaw J.J., and Dye C. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 186 9 (2002) 1314-1320
5. Moreno J., Nieto J., Chamizo C., Gonzalez F., Blanco F., Barker D.C., et al. The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy. Vet Immunol Immunopathol 71 3-4 (1999) 181-195
6. Baneth G., and Shaw S.E. Chemotherapy of canine leishmaniosis. Vet Parasitol 106 4 (2002) 315-324
7. Pasa S., Toz S.O., Voyvoda H., and Ozbel Y. Clinical and serological follow-up in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate. Vet Parasitol 128 3-4 (2005) 243-249
8. Pennisi M.G., De Majo M., Masucci M., Britti D., Vitale F., and Del Maso R. Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin. Vet Rec 156 11 (2005) 346-349
9. Alvar J., Molina R., San Andres M., Tesouro M., Nieto J., Vitutia M., et al. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann Trop Med Parasitol 88 4 (1994) 371-378
10. Tesh R.B. Control of zoonotic visceral leishmaniasis: is it time to change strategies?. Am J Trop Med Hyg 52 3 (1995) 287-292
11. Ashford D.A., David J.R., Freire M., David R., Sherlock I., Eulalio M.C., et al. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg 59 1 (1998) 53-57
12. Carrillo E., Ahmed S., Goldsmith-Pestana K., Nieto J., Osorio Y., Travi B., et al. Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. Vaccine 25 8 (2007) 1534-1543
13. Fujiwara R.T., Vale A.M., Franca da Silva J.C., da Costa R.T., Quetz Jda S., Martins Filho O.A., et al. Immunogenicity in dogs of three recombinant antigens (TSA LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 36 5-6 (2005) 827-838
14. Requena J.M., Iborra S., Carrion J., Alonso C., and Soto M. Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther 4 9 (2004) 1505-1517
15. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto RN). Vaccine 19 9-10 (2000) 1082-1092
16. Molano I., Alonso M.G., Miron C., Redondo E., Requena J.M., Soto M., et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 92 1-2 (2003) 1-13
17. Lemesre J.L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 22 (2005) 2825-2840
18. Moreno J., Nieto J., Masina S., Canavate C., Cruz I., Chicharro C., et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25 29 (2007) 5290-5300
19. Gradoni L., Foglia Manzillo V., Pagano A., Piantedosi D., De Luna R., Gramiccia M., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23 45 (2005) 5245-5251
20. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 19-20 (2003) 2474-2484
21. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23 28 (2005) 3716-3725
22. Poot J., Spreeuwenberg K., Sanderson S.J., Schijns V.E., Mottram J.C., Coombs G.H., et al. Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum. Vaccine 24 14 (2006) 2460-2468
23. Zugel U., and Kaufmann S.H. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 12 1 (1999) 19-39
24. Skeiky Y.A., Benson D.R., Guderian J.A., Whittle J.A., Bacelar O., Carvalho E.M., et al. Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun 63 10 (1995) 4105-4114
25. Rico A.I., Angel S.O., Alonso C., and Requena J.M. Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83. Mol Immunol 36 17 (1999) 1131-1139
26. Morell M., Thomas M.C., Caballero T., Alonso C., and Lopez M.C. The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection. Vaccine 24 49-50 (2006) 7046-7055
27. Miller M.J., Wrightsman R.A., and Manning J.E. Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response. Exp Parasitol 84 2 (1996) 156-167
28. Saravia N.G., Hazbon M.H., Osorio Y., Valderrama L., Walker J., Santrich C., et al. Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana. Vaccine 23 8 (2005) 984-995
29. Jardim A., Funk V., Caprioli R.M., and Olafson R.W. Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochem J 305 Pt 1 (1995) 307-313
30. Jardim A., Hanson S., Ullman B., McCubbin W.D., Kay C.M., and Olafson R.W. Cloning and structure-function analysis of the Leishmania donovani kinetoplastid membrane protein-11. Biochem J 305 Pt 1 (1995) 315-320
31. Berberich C., Requena J.M., and Alonso C. Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein. Exp Parasitol 85 1 (1997) 105-108
32. Kemp M., Kurtzhals J.A., Christensen C.B., Kharazmi A., Jardim A., Bendtzen K., et al. Production of interferon-gamma and interleukin-4 by human T cells recognizing Leishmania lipophosphoglycan-associated protein. Immunol Lett 38 2 (1993) 137-144
33. Kurtzhals J.A., Hey A.S., Jardim A., Kemp M., Schaefer K.U., Odera E.O., et al. Dichotomy of the human T cell response to Leishmania antigens II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin Exp Immunol 96 3 (1994) 416-421
34. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174 11 (2005) 7160-7171
35. Abranches P., Silva-Pereira M.C., Conceicao-Silva F.M., Santos-Gomes G.M., and Janz J.G. Canine leishmaniasis: pathological and ecological factors influencing transmission of infection. J Parasitol 77 4 (1991) 557-561
36. Moreno J., and Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol 18 9 (2002) 399-405
37. Rico A.I., Del Real G., Soto M., Quijada L., Martinez A.C., Alonso C., et al. Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice. Infect Immun 66 1 (1998) 347-352
38. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 4 (2001) 402-408
39. Young D.B. Heat-shock proteins: immunity and autoimmunity. Curr Opin Immunol 4 4 (1992) 396-400
40. Strauss-Ayali D., Baneth G., Shor S., Okano F., and Jaffe C.L. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs. Int J Parasitol 35 1 (2005) 63-73
41. Chamizo C., Moreno J., and Alvar J. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol 103 1-2 (2005) 67-75
42. Rafati S., Zahedifard F., and Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24 12 (2006) 2169-2175
43. Pinelli E., Killick-Kendrick R., Wagenaar J., Bernadina W., Del Real G., and Ruitenberg. J. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 62 1 (1994) 229-235
44. Quijada L., Requena J.M., Soto M., and Alonso C. During canine viscero-cutaneous leishmaniasis the anti-Hsp70 antibodies are specifically elicited by the parasite protein. Parasitology 112 Pt 3 (1996) 277-284
45. Quijada L., Requena J.M., Soto M., and Alonso C. Analysis of the antigenic properties of the L. infantum Hsp70: design of synthetic peptides for specific serodiagnosis of human leishmaniasis. Immunol Lett 63 3 (1998) 169-174
46. MacFarlane J., Blaxter M.L., Bishop R.P., Miles M.A., and Kelly J.M. Identification and characterisation of a Leishmania donovani antigen belonging to the 70-kDa heat-shock protein family. Eur J Biochem 190 2 (1990) 377-384
47. Skeiky Y.A., Benson D.R., Costa J.L., Badaro R., and Reed S.G. Association of Leishmania heat shock protein 83 antigen and immunoglobulin G4 antibody titers in Brazilian patients with diffuse cutaneous leishmaniasis. Infect Immun 65 12 (1997) 5368-5370
48. Rico A.I., Girones N., Fresno M., Alonso C., and Requena J.M. The heat shock proteins, Hsp70 and Hsp83, of Leishmania infantum are mitogens for mouse B cells. Cell Stress Chaperones 7 4 (2002) 339-346
49. Segura E.L., Paulone I., Cerisola J., and Cappa S.M. Experimental Chagas' disease: protective activity in relation with subcellular fractions of the parasite. J Parasitol 62 1 (1976) 131-133
50. Segura E.L., Vazquez C., Bronzina A., Campos J.M., Cerisola J.A., and Cappa S.M. Antigens of the subcellular fractions of Trypanosoma cruzi. II. Flagellar and membrane fraction. J Protozool 24 4 (1977) 540-543
51. Berberich C., Machado G., Morales G., Carrillo G., Jimenez-Ruiz A., and Alonso C. The expression of the Leishmania infantum KMP-11 protein is developmentally regulated and stage specific. Biochim Biophys Acta 1442 2-3 (1998) 230-237
52. Requena J.M., Alonso C., and Soto M. Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol Today 16 6 (2000) 246-250
53. Kemp M, Kurtzhals JA, Kharazmi A, Theander TG. Interferon-gamma and interleukin-4 in human Leishmania donovani infections. Immunol Cell Biol 1993;71(Pt 6):583-7.
54. Stebeck C.E., Beecroft R.P., Singh B.N., Jardim A., Olafson R.W., Tuckey C., et al. Kinetoplastid membrane protein-11 (KMP-11) is differentially expressed during the life cycle of African trypanosomes and is found in a wide variety of kinetoplastid parasites. Mol Biochem Parasitol 71 1 (1995) 1-13